HeimSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Við síðustu lokun
1.688,80 ₹
Dagbil
1.679,30 ₹ - 1.694,80 ₹
Árabil
1.460,90 ₹ - 1.960,35 ₹
Markaðsvirði
4,06 bn INR
Meðalmagn
2,82 m.
V/H-hlutf.
35,78
A/V-hlutfall
0,95%
Aðalkauphöll
NSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (INR) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 129,59 ma. | 8,14% |
Rekstrarkostnaður | 75,61 ma. | 20,16% |
Nettótekjur | 21,50 ma. | -19,01% |
Hagnaðarhlutfall | 16,59 | -25,10% |
Hagnaður á hvern hlut | 10,01 | -13,02% |
EBITDA | 34,05 ma. | 9,13% |
Virkt skatthlutfall | 33,68% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (INR) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 249,88 ma. | 30,89% |
Heildareignir | 921,01 ma. | 7,77% |
Heildarskuldir | 196,15 ma. | 6,85% |
Eigið fé alls | 724,86 ma. | — |
Útistandandi hlutabréf | 2,39 ma. | — |
Eiginfjárgengi | 5,59 | — |
Arðsemi eigna | — | — |
Ávöxtun eigin fjár | 9,40% | — |
Peningaflæði
Breyting á handbæru fé
| (INR) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 21,50 ma. | -19,01% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Stofnsett
1983
Höfuðstöðvar
Vefsvæði
Starfsfólk
43.000
